Phibro Animal Health (NASDAQ:PAHC) was upgraded by BidaskClub from a “sell” rating to a “hold” rating in a research note issued to investors on Wednesday.
A number of other research analysts have also recently issued reports on the stock. Zacks Investment Research cut shares of Phibro Animal Health from a “buy” rating to a “hold” rating in a report on Wednesday, April 11th. ValuEngine raised shares of Phibro Animal Health from a “hold” rating to a “buy” rating in a report on Wednesday, February 28th. Morgan Stanley increased their price objective on shares of Phibro Animal Health from $30.00 to $36.00 and gave the stock an “underweight” rating in a research note on Wednesday, February 7th. Finally, Credit Suisse Group increased their price objective on shares of Phibro Animal Health from $37.00 to $39.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 6th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $38.20.
NASDAQ PAHC opened at $44.00 on Wednesday. The firm has a market capitalization of $1,712.14, a price-to-earnings ratio of 29.14, a P/E/G ratio of 3.02 and a beta of 0.93. Phibro Animal Health has a 12-month low of $27.20 and a 12-month high of $44.20. The company has a debt-to-equity ratio of 1.82, a current ratio of 3.12 and a quick ratio of 1.75.
Phibro Animal Health (NASDAQ:PAHC) last posted its quarterly earnings results on Monday, February 5th. The company reported $0.44 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.38 by $0.06. The business had revenue of $205.90 million during the quarter, compared to analysts’ expectations of $194.90 million. Phibro Animal Health had a net margin of 7.90% and a return on equity of 40.49%. The business’s quarterly revenue was up 7.5% on a year-over-year basis. During the same quarter last year, the company posted $0.39 earnings per share. equities analysts anticipate that Phibro Animal Health will post 1.69 earnings per share for the current year.
In other news, insider Jack Bendheim sold 36,000 shares of the stock in a transaction on Thursday, March 1st. The shares were sold at an average price of $38.35, for a total value of $1,380,600.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Larry Lee Miller sold 54,572 shares of the stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $35.36, for a total transaction of $1,929,665.92. Following the completion of the sale, the chief operating officer now owns 8,582 shares in the company, valued at approximately $303,459.52. The disclosure for this sale can be found here. Insiders sold 276,056 shares of company stock worth $10,495,260 in the last quarter. Company insiders own 51.88% of the company’s stock.
Several large investors have recently added to or reduced their stakes in the company. Copper Rock Capital Partners LLC increased its stake in shares of Phibro Animal Health by 9.6% in the fourth quarter. Copper Rock Capital Partners LLC now owns 631,876 shares of the company’s stock worth $21,326,000 after acquiring an additional 55,235 shares during the period. Goldman Sachs Group Inc. grew its position in Phibro Animal Health by 17.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 476,391 shares of the company’s stock valued at $15,959,000 after buying an additional 69,063 shares during the period. Dimensional Fund Advisors LP grew its position in Phibro Animal Health by 11.8% during the third quarter. Dimensional Fund Advisors LP now owns 465,297 shares of the company’s stock valued at $17,239,000 after buying an additional 49,296 shares during the period. Renaissance Technologies LLC grew its position in Phibro Animal Health by 16.4% during the fourth quarter. Renaissance Technologies LLC now owns 463,496 shares of the company’s stock valued at $15,527,000 after buying an additional 65,396 shares during the period. Finally, Millennium Management LLC grew its position in Phibro Animal Health by 64.3% during the fourth quarter. Millennium Management LLC now owns 419,998 shares of the company’s stock valued at $14,070,000 after buying an additional 164,424 shares during the period. Hedge funds and other institutional investors own 48.08% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Phibro Animal Health (PAHC) Lifted to “Hold” at BidaskClub” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another domain, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/18/phibro-animal-health-pahc-lifted-to-hold-at-bidaskclub.html.
About Phibro Animal Health
Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition company primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture.
Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.